Early access
Sign in
Taking people in ItalyPhase 3

Testing elecoglipron for weight loss in adults with excess body weight

Tests elecoglipron against a dummy pill in adults with obesity or overweight.

Key facts

Who runs it
AstraZeneca AB
Where
Bologna, Catania, Chieti, Florence, Latina, Milan, Pisa, Ravenna, Rome, and San Donato Milanese, ItalySee the 11 sitesAlso in 3 other countries, 53 sites
Registry title
A trial to learn how safe elecoglipron is and how well it works in adults living with obesity or excess body weight with or without type 2 diabetes
Status
Recruiting
Phase
Phase 3
People taking part
1,010 people, planned
Started
11 Aug 2026
Expected to end
30 Jul 2029
Type of study
Interventional
Record updated
8 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with obesity or overweight. Some may have type 2 diabetes, others not. It tests elecoglipron against placebo for weight loss.

Age
18 years or older
Sex
Women and men can join.
Disease stage
Study 1: BMI 30 kg/m2 or higher, or BMI from 27 to under 30 kg/m2 with at least one weight-related condition (high blood pressure, prediabetes, abnormal blood fats, heart and blood vessel disease, or sleep apnea). Study 2: BMI 27 kg/m2 or higher with type 2 diabetes.
Earlier treatment
At least one self-reported unsuccessful diet attempt to lose weight. Body weight stable for 90 days before screening (within 5% change).
Biomarker or test result
Study 2: type 2 diabetes diagnosis, or no diagnosis but HbA1c 6.5% (48 mmol/mol) or higher at screening.

Main reasons for not taking part

  • Study 1: diagnosis of type 1 or type 2 diabetes
  • Study 2: type 1 diabetes, or HbA1c 10% (86 mmol/mol) or higher
  • Study 2: current or expected treatment for diabetic eye disease, or more than one severe low blood sugar episode in the past 180 days
  • Past acute pancreatitis (unless from resolved gallstones and gallbladder removal) or chronic pancreatitis
  • Medullary thyroid cancer or multiple endocrine neoplasia type 2 in the person or in close family

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Legal age of consent and at least 18 years old
  • Study 1 - ○ BMI ≥ 30 kg/m2 or ○ 27 kg/m2 ≤ BMI < 30 kg/m2 with at least one of the following weight-related comorbidities: ○ Hypertension ○ Prediabetes ○ Dyslipidemia ○ Cardiovascular disease ○ Obstructive sleep apnea
  • Study 2 - BMI ≥ 27 kg/m2 and T2DM defined as below: ○ Established diagnosis of T2DM ○ Without established diagnosis of T2DM and HbA1c ≥ 6.5% (48 mmol/mol) at the screening visit
  • Stable body weight (self-reported or documented) for 90 days prior to the screening visit (± 5% body weight change)
  • History of at least one self-reported unsuccessful dietary effort to lose body weight

Who cannot take part

  • History of acute (unless due to previously resolved gallstone pancreatitis and post-cholecystectomy) or chronic pancreatitis
  • History/family history (first degree biologic relatives) of medullary thyroid cancer or multiple endocrine neoplasia type 2
  • Study 2 - Any of the following medical history, laboratory values, or complications related to diabetes: ○ T1DM ○ HbA1c ≥ 10% (86 mmol/mol) at the screening visit ○ Currently receiving, or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema.○ Have had more than one episode of severe hypoglycemia within 180 days prior to the screening visit, or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms
  • Study 1 - Established diagnosis of T1DM or T2DM

Where in Italy

Also in 3 other countries, 53 sites

  • Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere ScientificoBologna, ItalyTaking people
  • ARNAS Garibaldi Di CataniaCatania, ItalyTaking people
  • CAST - Center for Advanced Studies and Technology di ChietiChieti, ItalyTaking people
  • Azienda Ospedaliero-Universitaria CareggiFlorence, ItalyTaking people
  • Ospedale Santa Maria Goretti LatinaLatina, ItalyTaking people
  • ASST Fatebenefratelli SaccoMilan, ItalyTaking people
  • Azienda Ospedaliero Universitaria PisanaPisa, ItalyTaking people
  • Azienda Unità Sanitaria Locale della RomagnaRavenna, ItalyTaking people
  • Azienda Ospedaliero-Universitaria Policlinico Umberto IRome, ItalyTaking people
  • Fondazione Policlinico Universitario Campus Bio-medico In Forma A Bbreviata FonRome, ItalyTaking people
  • Policlinico San Donato S.p.A.San Donato Milanese, ItalyTaking people

About the trial

What the trial wants to find out

To determine whether elecoglipron is superior to placebo for percent body weight loss in two independent studies, in adults with obesity or overweight with or without T2DM

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Master Protocol to Evaluate the Efficacy and Safety of Elecoglipron in Participants with Obesity or Overweight with or without Type 2 Diabetes Mellitus (Embold)
Plain-language title
Testing elecoglipron for weight loss in adults with excess body weightGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
8 September 2026